open access

Vol 88, No 6 (2017)
Research paper
Published online: 2017-06-30
Get Citation

The assessment of overall survival (OS) after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland

Zbigniew Teter1, Andrzej Śliwczyński, Melania Brzozowska, Marcin Świerkowski, Andrzej Jacyna, Jarosław Pinkas, Aleksandra Sierocka2, Michał Marczak, Anna Dańska-Bidzińska, Mariusz Bidziński, Waldemar Wierzba
DOI: 10.5603/GP.a2017.0056
·
Pubmed: 28727127
·
Ginekol Pol 2017;88(6):296-301.
Affiliations
  1. National Health Fund, Warsaw, Poland, Poland
  2. Department of Neurology, Copernicus Memorial Hospital in Lodz, Comprehensive Cancer Centre and Traumatology, Lodz, Poland, Poland

open access

Vol 88, No 6 (2017)
ORIGINAL PAPERS Gynecology
Published online: 2017-06-30

Abstract

Objectives: In 2013 malignant endometrial cancers have amounted to 7.3% of all cancers diagnosed among women in the report by the Polish National Cancer Registry Raw prevalence rate amounted to 28.7, whereas standardised prevalence rate 15.6 per 100 000 population. Among the causes of death, these cancers amounted to 3% and were ranked ninth on the list of the most common causes of oncologic mortality of women. In the year 2013 a total of 1243 women died of malignant endometrial cancers. A stable increase of malignant endometrial cancer incidence has been observed for 2 decades. Despite that fact, the increase of the mortality incidence is at a much lower level, which demonstrates the much higher effectiveness of the treatment of such cancers. The recording rate of the malignant endometrial cancer mortality amounts to 95%, so the presented absolute numbers are reliable. Examining the clinical stages of malignant endometrial cancers, we can establish that approx. 85% of them are diagnosed at stage I or II according to the FIGO classification. Patients with advanced stages of cancer represent less than 15%.

Material and methods: retrospective analysis of endometrial body cancer prevalence data for the entire population of Poland, assessment of malignant endometrial cancer prevalence in the years 2008–2015 and overall survival probability in the population of patients undergoing adjuvant chemotherapy.

Results: The number of patients with a diagnosed malignant endometrial cancer within the studied period in Poland remains on a stable level (2008 — 30.6 thousand patients, 2015 — 40.2 thousand patients). Among all listed patients with the indica­tion of C54 each year approx. 20% enters hospital treatment. System therapy with chemotherapy drugs was used in approx. 1–2% of patients treated in hospitals. The average age of the patients was 64.9 years, and the median age 65 years. The num­ber of observations was 2085, including 1088 censored observations. The average survival for the sample under study was 30.67 month (SD = ± 0.6); median survival time was 23.93 month. The number of censored observations was 1088 (52.16%). Probable survival of 1 year is achieved by 67.57% of patients, 2 years by 49.73%, 3 years by 40.68%, above 5 years 30.77%.

Conclusions: The incidence of endometrial cancer in Poland in the years 2008–2015 continues to grow at 5% upward trend (in Europe 3.4–5.9). In Poland in 2012, crude incidence rate for cancer of the uterus was 29.8 and did not differ significantly from the results in countries such as Finland, Slovakia, Sweden, Belgium and Bulgaria. The overall survival after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland shows considerable differences depending on the region of the country.

Abstract

Objectives: In 2013 malignant endometrial cancers have amounted to 7.3% of all cancers diagnosed among women in the report by the Polish National Cancer Registry Raw prevalence rate amounted to 28.7, whereas standardised prevalence rate 15.6 per 100 000 population. Among the causes of death, these cancers amounted to 3% and were ranked ninth on the list of the most common causes of oncologic mortality of women. In the year 2013 a total of 1243 women died of malignant endometrial cancers. A stable increase of malignant endometrial cancer incidence has been observed for 2 decades. Despite that fact, the increase of the mortality incidence is at a much lower level, which demonstrates the much higher effectiveness of the treatment of such cancers. The recording rate of the malignant endometrial cancer mortality amounts to 95%, so the presented absolute numbers are reliable. Examining the clinical stages of malignant endometrial cancers, we can establish that approx. 85% of them are diagnosed at stage I or II according to the FIGO classification. Patients with advanced stages of cancer represent less than 15%.

Material and methods: retrospective analysis of endometrial body cancer prevalence data for the entire population of Poland, assessment of malignant endometrial cancer prevalence in the years 2008–2015 and overall survival probability in the population of patients undergoing adjuvant chemotherapy.

Results: The number of patients with a diagnosed malignant endometrial cancer within the studied period in Poland remains on a stable level (2008 — 30.6 thousand patients, 2015 — 40.2 thousand patients). Among all listed patients with the indica­tion of C54 each year approx. 20% enters hospital treatment. System therapy with chemotherapy drugs was used in approx. 1–2% of patients treated in hospitals. The average age of the patients was 64.9 years, and the median age 65 years. The num­ber of observations was 2085, including 1088 censored observations. The average survival for the sample under study was 30.67 month (SD = ± 0.6); median survival time was 23.93 month. The number of censored observations was 1088 (52.16%). Probable survival of 1 year is achieved by 67.57% of patients, 2 years by 49.73%, 3 years by 40.68%, above 5 years 30.77%.

Conclusions: The incidence of endometrial cancer in Poland in the years 2008–2015 continues to grow at 5% upward trend (in Europe 3.4–5.9). In Poland in 2012, crude incidence rate for cancer of the uterus was 29.8 and did not differ significantly from the results in countries such as Finland, Slovakia, Sweden, Belgium and Bulgaria. The overall survival after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland shows considerable differences depending on the region of the country.

Get Citation

Keywords

chemotherapy, malignant endometrial cancer, Poland

About this article
Title

The assessment of overall survival (OS) after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland

Journal

Ginekologia Polska

Issue

Vol 88, No 6 (2017)

Article type

Research paper

Pages

296-301

Published online

2017-06-30

DOI

10.5603/GP.a2017.0056

Pubmed

28727127

Bibliographic record

Ginekol Pol 2017;88(6):296-301.

Keywords

chemotherapy
malignant endometrial cancer
Poland

Authors

Zbigniew Teter
Andrzej Śliwczyński
Melania Brzozowska
Marcin Świerkowski
Andrzej Jacyna
Jarosław Pinkas
Aleksandra Sierocka
Michał Marczak
Anna Dańska-Bidzińska
Mariusz Bidziński
Waldemar Wierzba

References (12)
  1. Didkowska J, Wojciechowska U. Nowotwory Złośliwe w Polsce w 2013 r Krajowy Rejestr Nowotworów MZ Warszawa 2015 (Malignant cancers in Poland in 2013. National Cancer Registry, Ministry of Health Warsaw. ; 2015.
  2. Kornafel J, Mądry R, Bidziński M. Nowotwory kobiecego układu płciowego. Zalecenia postępowania diagnostyczno terapeutycznego w nowotworach złośliwych – 2013. Pod red M Krzakowskiego PTOK 2013; 286 (Female reproductive system cancers. Recommendations for diagnostic and therapeutic proceedings in malignant cancers — 2013. Edited by M. Krzakowski PTOK 2013.
  3. Zwierko M. Epidemiologia nowotworów złozliwych trzonu macicy. In: Bidziński M. ed. Nowotwory trzonu macicy. CMKP 2011: 5–26.
  4. GLOBCAN 2012 IARC.-2.12.2016 Globcan.iarc.fr.
  5. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016; 26(1): 2–30.
  6. Iqbal J, Ginsburg OM, Wijeratne TD, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012; 38(4): 318–328.
  7. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311(8): 806–814.
  8. http://seer.cancer.gov/statfacts/html/corp. (6.06.2016).
  9. Tejerizo-García A, Jiménez-López JS, Muñoz-González JL, et al. Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. Onco Targets Ther. 2013; 9: 1305–1313.
  10. Chen T, Jansen L, Gondos A, et al. GEKID Cancer Survival Working Group. Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. BMC Cancer. 2012; 12: 128.
  11. Gondos A, Bray F, Brewster DH, et al. EUNICE Survival Working Group. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer. 2008; 44(10): 1463–1475.
  12. www.cancer.org.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl